Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
ClinicalTrials.gov study NCT05167643. IPD Sharing: NO. Countries: 1. Publications: 0.
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
ClinicalTrials.gov study NCT03322215. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthritis: an HR-pQCT Study
ClinicalTrials.gov study NCT04324892. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
ClinicalTrials.gov study NCT05979220. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
ClinicalTrials.gov study NCT05524584. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
ClinicalTrials.gov study NCT02023359. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
ClinicalTrials.gov study NCT05266105. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
ClinicalTrials.gov study NCT04197999. IPD Sharing: NO. Countries: 1. Publications: 0.
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
ClinicalTrials.gov study NCT06612814. IPD Sharing: NO. Countries: 1. Publications: 0.
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT05173103. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients
ClinicalTrials.gov study NCT07052734. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
ClinicalTrials.gov study NCT06172322. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT07164976. IPD Sharing: YES. Countries: 0. Publications: 0.
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
ClinicalTrials.gov study NCT07019363. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
ClinicalTrials.gov study NCT03913234. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
ClinicalTrials.gov study NCT04355520. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bone Microstructure After Gastrectomy Evaluating by Using HR-pQCT
ClinicalTrials.gov study NCT03398226. IPD Sharing: NO. Countries: 1. Publications: 0.
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ
ClinicalTrials.gov study NCT06176534. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
ClinicalTrials.gov study NCT06227117. IPD Sharing: NO. Countries: 1. Publications: 0.
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
ClinicalTrials.gov study NCT07237256. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.